Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov-Dec;47(6):594-9.
doi: 10.4103/0253-7613.169593.

Psychiatric aspects of phosphodiesterases: An overview

Vasantmeghna S Murthy  1 , Ajish G Mangot  1
Affiliations
Review

Psychiatric aspects of phosphodiesterases: An overview

Vasantmeghna S Murthy et al. Indian J Pharmacol. 2015 Nov-Dec.

Abstract

Phosphodiesterases (PDE) are exciting new targets in medical sciences. These enzymes are some of the key mediators of cellular functions in the body and hence are attractive sites for drug-induced modulations. With the finding that Tofisopam, a new anxiolytic, inhibits PDEs, the authors were inspired to look into the role of PDE and drugs acting on them in psychiatry. Hence, the review was undertaken. We found several research materials available highlighting the role of PDE in cellular functions and the possible newer etiological mechanisms of neuropsychiatric illnesses such as schizophrenia, depression/anxiety disorders, and cognitive dysfunction involving PDEs. We also found that there are many molecules acting on PDEs, which have the potential to alter the way we treat mental illnesses today. This article is intended to provide an in-depth look at these enzymes so that more cost-effective therapeutic molecules may be synthesized and marketed in India for managing mental illnesses.

Keywords: Affective disorders; anxiety; cognition; phosphodiesterase; phosphodiesterase inhibitor; schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phosphodiesterases and second messengers
Figure 2
Figure 2
Differential expression of phosphodiesterases in human body
See this image and copyright information in PMC

References

    1. Srivastava S, Bhatia MS, Gupta K, Rajdev K. Current update on evidence based literature of tofisopam. Delhi Psychiatry J. 2014;17:154–9.
    1. Rundfeldt C, Socala K, Wlaz P. The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm. 2010;117:1319–25. - PMC - PubMed
    1. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Molecular Cell Biology. 4th ed. Sec. 20.1. New York: W. H. Freeman; 2000. [Last accessed on 2015 Sep 20]. Overview of Extracellular Signaling. Available from: http://www.ncbi.nlm.nih.gov/books/NBK21517/
    1. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev. 2006;58:488–520. - PubMed
    1. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006;147(Suppl 1):S252–7. - PMC - PubMed

MeSH terms